AbbVie Puts Final Nail In Rova-T's Coffin After Another Trial Failure
AbbVie already wrote off $4bn of the $5.8bn Stemcentrx acquisition that gave it the antibody-drug-conjugate, but now the company has ended all Rova-T development.
You may also be interested in...
Liposomal chemotherapy drug Onivyde achieved a 44% response rate in second-line small cell lung cancer patients, providing preliminary validation of its ability to improve outcomes in the hard-to-treat disease.
Mega-merger's top US drug candidates are seeking space in crowded fields. That means they have to get through the FDA fast, and priority review vouchers figure prominently in both improving and lowering the odds.
AbbVie will gain the $3.58bn Botox business, a women's health franchise and gastrointestinal products in an opportunistic acquisition intended to reduce the company's dependence on Humira.